Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We have examined whether the apoptosis‐specific protein p45ASP and human Apg5 are identical proteins. Like p45ASP, myc‐hApg5 cross‐reacted with a c‐Jun antibody and ∼50% of myc‐hApg5 was bound to a Triton X‐100‐insoluble fraction in HeLa cells. However, soluble myc‐hApg5 was degraded during apoptosis induced by staurosporine or TNFα/cycloheximide whilst expression of soluble p45ASP was stabilised. Furthermore, myc‐hApg5 degradation was blocked by the caspase inhibitor Boc‐Asp(OMe)FMK whilst p45ASP expression was eliminated. Moreover, myc‐hApg5 (∼32 kDa) never assumed the size of p45ASP (45 kDa). It is therefore likely that p45ASP and human Apg5 are distinct proteins although they do share some common characteristics.

More information Original publication

DOI

10.1016/s0014-5793(02)03497-x

Type

Journal article

Publisher

Wiley

Publication Date

2002-11-06T00:00:00+00:00

Volume

531

Pages

168 - 172

Total pages

4